Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer

Molecular Cancer Therapeutics

Volumn 6, Issue 5, 2007, Pages 1509-1516

  Jimeno, Antonio ^a   Hallur, Gurulingappa ^b   Chan, Audrey ^a   Zhang, Xiangfeng ^a   Cusatis, George ^a   Chan, Fonda ^a   Shah, Preeti ^a   Chen, Rongbing ^a   Hamel, Ernest ^d   Garrett Mayer, Elizabeth ^c   Khan, Saeed ^b,e   Hidalgo, Manuel ^a,e  

^a Gastrointestinal Cancer Program   (United States)

^b Chemical Therapeutics Program   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; SG 410; SG 430; SULFUR BENZOYLPHENYLUREA DERIVATIVE; TAU PROTEIN; TUBULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA SEQUENCE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; MICE; MICE, NUDE; MICROTUBULES; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; PHENYLUREA COMPOUNDS; SULFUR; TAU PROTEINS; TAXOIDS; TUBULIN;

EID: 34250705854     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0592     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Yeo TP, Hruban RH, Leach SD, et al. Pancreatic cancer. Curr Probl Cancer 2002;26:176-275.
3. Downing KH, Nogales E. Tubulin structure: insights into microtubule properties and functions. Curr Opin Struct Biol 1998;8:785-91.
4. Sorger PK, Dobles M, Tournebize R, Hyman AA. Coupling cell division and cell death to microtubule dynamics. Curr Opin Cell Biol 1997;9:807-14.
5. Jordan A, Hadfield JA, Lawrence NJ, McGown AT. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev 1998;18:259-96.
6. Okada H, Koyanagi T, Yamada N, Haga T. Synthesis and antitumor activities of novel benzoylphenylurea derivatives. Chem Pharm Bull (Tokyo) 1991;39:2308-15.
7. Okada H, Koyanagi T, Yamada N. Synthesis and antitumor activities of prodrugs of benzoylphenylureas. Chem Pharm Bull (Tokyo) 1994;42:57-61.
8. Okada H, Kato M, Koyanagi T, Mizuno K. Synthesis and antitumor activities of water-soluble benzoylphenylureas. Chem Pharm Bull (Tokyo) 1999;47:430-3.
9. Rudek MA, Zhao M, Smith NF, et al. In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent. Clin Cancer Res 2005;11:8503-11.
10. Messersmith WA, Rudek MA, Baker SD, et al. Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumors. Eur J Cancer 2007;43:78-86.
11. Gurulingappa H, Amador ML, Zhao M, et al. Synthesis and antitumor evaluation of benzoylphenylurea analogs. Bioorg Med Chem Lett 2004;14:2213-6.
12. Hallur G, Jimeno A, Dalrymple S, et al. Benzoylphenylurea sulfur analogues with potent antitumor activity. J Med Chem 2006;49:2357-60.
13. Rubio-Viqueira B, Jimeno A, Cusatis G, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 2006;12:4652-61.
14. Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci U S A 1988;85:4051-5.
15. Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J 1989;8:393-9.
16. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 1989;3:519-26.
17. Veitia R, Bissery MC, Martinez C, Fellous A. Tau expression in model adenocarcinomas correlates with docetaxel sensitivity in tumour-bearing mice. Br J Cancer 1998;78:871-7.
18. Rouzier R, Rajan R, Wagner P, et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A 2005;102:8315-20.
19. Seve P, Mackey J, Isaac S, et al. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005;4:2001-7.
20. Monzo M, Rosell R, Sanchez JJ, et al. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 1999;17:1786-93.
21. Hamel E. Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin. Cell Biochem Biophys 2003;38:1-22.
22. Verdier-Pinard P, Lai JY, Yoo HD, et al. Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells. Mol Pharmacol 1998;53:62-76.
23. Smith LM, Sanders JZ, Kaiser RJ, et al. Fluorescence detection in automated DNA sequence analysis. Nature 1986;321:674-9.
24. McCombie WR, Heiner C, Kelley JM, Fitzgerald MG, Gocayne JD. Rapid and reliable fluorescent cycle sequencing of double-stranded templates. DNA Seq 1992;2:289-96.
25. Paull KD, Lin CM, Malspeis L, Hamel E. Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data. Cancer Res 1992;52:3892-900.
26. Rougier P, Adenis A, Ducreux M, et al. A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer 2000;36:1016-25.
27. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
28. Wilhelmsen KC, Lynch T, Pavlou E, Higgins M, Nygaard TG. Localization of disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22. Am J Hum Genet 1994;55:1159-65.
29. Poorkaj P, Sharma V, Anderson L, et al. Missense mutations in the chromosome 14 familial Alzheimer's disease presenilin 1 gene. Hum Mutat 1998;11:216-21.
30. Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998;393:702-5.
31. Spillantini MG, Murrell JR, Goedert M, et al. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A 1998;95:7737-41.
32. D'Souza I, Poorkaj P, Hong M, et al. Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc Natl Acad Sci U S A 1999;96:5598-603.
33. Rizzu P, Van Swieten JC, Joosse M, et al. High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands. Am J Hum Genet 1999;64:414-21.
34. Yoshida H, Crowther RA, Goedert M. Functional effects of tau gene mutations deltaN296 and N296H. J Neurochem 2002;80:548-51.
35. Sale S, Sung R, Shen P, et al. Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers. Mol Cancer Ther 2002;1:215-25.
36. Achiwa H, Sato S, Shimizu S, et al. Analysis of beta-tubulin gene alteration in human lung cancer cell lines. Cancer Lett 2003;201:211-6.